Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRCA2 oncogenic variants status confers therapeutic sensitivity to Abiraterone acetate, Niraparib, Prednisolone in patients with Prostate Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved niraparib in combination with abiraterone acetate and prednisolone for reimbursement as a treatment option for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.
This statement is based on a regulatory approval from the Health Service Executive:
Niraparib in combination with abiraterone acetate (Akeega) and predniSONE/prednisoLONE for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.